Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations

AG Sowalsky, H Ye, M Bhasin, EM Van Allen, M Loda… - Cancer research, 2018 - AACR
Primary prostate cancer can have extensive microheterogeneity, but its contribution to the
later emergence of metastatic castration-resistant prostate cancer (mCRPC) remains …
被引用次数：62 相关文章

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations

AG Sowalsky, H Ye, M Bhasin… - Cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Primary prostate cancer can have extensive microheterogeneity, but its contribution to the
later emergence of metastatic castration-resistant prostate cancer (mCRPC) remains …
[HTML] nih.gov

[HTML][HTML] Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations

AG Sowalsky, H Ye, M Bhasin, EM Van Allen… - Cancer …, 2018 - ncbi.nlm.nih.gov
Primary prostate cancer (PCa) can have extensive microheterogeneity, but its contribution to
the later emergence of metastatic castration-resistant PCa (mCRPC) remains unclear. In this …

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.

AG Sowalsky, H Ye, M Bhasin, EM Van Allen… - Cancer …, 2018 - europepmc.org
Primary prostate cancer (PCa) can have extensive microheterogeneity, but its contribution to
the later emergence of metastatic castration-resistant PCa (mCRPC) remains unclear. In this …

[引用][C] Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations

AG Sowalsky, H Ye, M Bhasin, EM Van Allen, M Loda… - Cancer …, 2018 - cir.nii.ac.jp
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with
Diverse Subclonal Oncogenic Alterations | CiNii Research CiNii 国立情報学研究所 学術情報 …